

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



May 1, 2025

Company name: Takara Bio Inc. (Securities code: 4974;
Prime Market)
Headquarters Nojihigashi 7-4-38, Kusatsu, Shiga, Japan
Representative Koichi Nakao, President & CEO
Contact Noritaka Nishiwaki, Executive Officer, in
charge of PR & IR Department
Telephone (+81)77-565-6970
Website <https://www.takara-bio.co.jp/>

(Progress of Matters Previously Disclosed) Notice Concerning the Absorption-type Merger (Simplified Merger) of the Wholly Owned Subsidiary

Takara Bio Inc. (“Takara Bio”) hereby announces that announced in the "Notice Regarding the Absorption-Type Merger (Simplified Merger) of a Wholly Owned Subsidiary" dated March 27, 2025, to absorb and merge its wholly owned subsidiary, ViSpot, Inc. (“ViSpot”), we are completed as scheduled on May 1, 2025.

1. Purpose of the Absorption-type Merger

The merger aims to rationalize management and accelerate business expansion.

2. Overview of companies involved in the Absorption-type Merger

	Company surviving the absorption-type merger	Company disappearing in the absorption-type merger
(1) Name	Takara Bio Inc.	ViSpot, Inc.
(2) Location	Nojihigashi 7-4-38, Kusatsu, Shiga, Japan	KCMI, 6-3-5, Minatojimaminami-machi, Chuo-ku, Kobe, Hyogo, JAPAN
(3) Job title and name of representative	Koichi Nakao, President & CEO	Yuko Mori, President & CEO
(4) Description of business	Manufacturing and sales of reagents and instruments, CDMO, Gene therapy business	Viral safety testing services
(5) Share capital	14,965 million yen (as of the end of February 2025)	40 million yen (as of the end of February 2025)
(6) Date of establishment	April, 2002	September, 2017
(7) Number of issued shares	120,415,600 shares (as of the end of February 2025)	800 shares (as of the end of February 2025)
(8) Fiscal year-end	March 31	December 31

3. Future outlook

The impact on the consolidated business performance will be minor.